全文获取类型
收费全文 | 1049篇 |
免费 | 65篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 14篇 |
妇产科学 | 11篇 |
基础医学 | 112篇 |
口腔科学 | 26篇 |
临床医学 | 209篇 |
内科学 | 249篇 |
皮肤病学 | 47篇 |
神经病学 | 28篇 |
特种医学 | 23篇 |
外科学 | 142篇 |
综合类 | 4篇 |
预防医学 | 49篇 |
眼科学 | 22篇 |
药学 | 60篇 |
中国医学 | 1篇 |
肿瘤学 | 111篇 |
出版年
2021年 | 6篇 |
2020年 | 10篇 |
2019年 | 8篇 |
2018年 | 9篇 |
2017年 | 12篇 |
2016年 | 18篇 |
2015年 | 19篇 |
2014年 | 28篇 |
2013年 | 45篇 |
2012年 | 42篇 |
2011年 | 78篇 |
2010年 | 33篇 |
2009年 | 43篇 |
2008年 | 69篇 |
2007年 | 80篇 |
2006年 | 79篇 |
2005年 | 94篇 |
2004年 | 56篇 |
2003年 | 49篇 |
2002年 | 61篇 |
2001年 | 22篇 |
2000年 | 12篇 |
1999年 | 37篇 |
1998年 | 15篇 |
1997年 | 17篇 |
1996年 | 12篇 |
1995年 | 7篇 |
1994年 | 9篇 |
1993年 | 5篇 |
1992年 | 10篇 |
1991年 | 4篇 |
1989年 | 6篇 |
1988年 | 10篇 |
1987年 | 7篇 |
1986年 | 7篇 |
1985年 | 11篇 |
1984年 | 4篇 |
1983年 | 6篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 5篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1974年 | 4篇 |
1972年 | 3篇 |
1971年 | 4篇 |
1968年 | 5篇 |
1966年 | 4篇 |
1940年 | 3篇 |
排序方式: 共有1115条查询结果,搜索用时 46 毫秒
81.
82.
Simon GR Schell MJ Begum M Kim J Chiappori A Haura E Antonia S Bepler G 《Cancer》2012,118(9):2525-2531
BACKGROUND:
Excision repair cross complementing 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) are molecular determinants that predict sensitivity or resistance to platinum agents and gemcitabine, respectively. Tailored therapy using these molecular determinants suggested patient benefit in a previously reported phase 2 trial. Here, we report an individual patient analysis of prospectively accrued patients who were treated with the “personalized therapy” approach versus other “standard,” noncustomized approaches.METHODS:
Patients who had nonsmall cell lung cancer (NSCLC) with extranodal metastatic disease and an Eastern Cooperative Oncology Group performance status of 0/1 were accrued to 4 phase 2 clinical trials conducted at the H. Lee Moffitt Cancer Center: Trial A (first‐line carboplatin/gemcitabine followed by docetaxel), Trial B (docetaxel and gefitinib in patients aged ≥70 years), Trial C (combination therapy with carboplatin/paclitaxel/atrasentan), and Trial D (personalized therapy based on ERCC1 and RRM1 expression). Patients with low RRM1/low ERCC1 expression received gemcitabine/carboplatin, patients with low RRM1/high ERCC1 expression received gemcitabine/docetaxel, patients with high RRM1/low ERCC1 expression received docetaxel/carboplatin, and patients with high RRM1/high ERCC1 expression received vinorelbine/docetaxel. Patients who were treated on Trials A, B, and C were pooled together and analyzed as the “standard therapy” group. Patients accrued to Trial D were called the “personalized therapy” group. Individual patient data were updated as of February 8, 2011. Overall survival (OS) and progression‐free survival (PFS) were estimated using the Kaplan‐Meier method.RESULTS:
There were statistically significant improvements between the personalized therapy group versus the standard therapy group in response (44% vs 22%; P = .002), OS (median: 13.3 months vs 8.9 months; P = .016), and PFS (median: 7.0 months vs 4.3 months; P = .03).CONCLUSIONS:
The results from individual patient analyses suggest that ERCC1 and RRM1/tailored selection of first‐line therapy improved survival over standard treatment‐selection approaches. Cancer 2012. © 2011 American Cancer Society. 相似文献83.
Gerhard SCHWAB Gerold WETSCHER Gunther KLIMA Thomas MAIRINGER Rudolph POINTNER Ernst BODNER 《Digestive endoscopy》1991,3(4):507-510
Abstract: A new method of orotracheal intubation in rats which was developed to prevent apnea during upper gastrointestinal endoscopiy is described. After the anesthetized animals are relaxed with an I. V. injection of Vecuronium, orotracheal intubation was performed with a thin endoscope under complete visual control. After relaxation is achieved the glottis is wide open and intubation can be performed carefully without any medianical irritation of the larynx. After placement of the tube in the trachea, the fiberoptic was removed and pressure–controlled ventilation occurred. This technique can be widely applied in any kind of rat experiment, where controlled ventilation is required. 相似文献
84.
Hugo Gerold 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》1866,12(1):31-33
Ohne Zusammenfassung 相似文献
85.
Anke M. van Gestel Health Scientist Gerold Stucki MD MS Professor of Physical Medicine Rehabilitation 《Best Practice & Research: Clinical Rheumatology》1999,13(4):629-644
There are two major aspects to evaluate in patients with established RA, namely (i) the state or progress of the disease, and (ii) the effects of specific interventions. The evaluation should include reliable, valid and sensitive measures of disease activity, tissue damage and health status. It is important to recognise that measures of disease activity can be influenced by tissue damage as well. Also, in established RA, health status is likely to be influenced by both disease activity and tissue damage. Whether current rules concerning improvement or remission, which were developed in the context of early RA, can be applied to established disease has to be investigated. While use of radiographs is the current standard method of assessing damage in established RA, range-of-motion measures and muscle strength indices may be a more practical and an equally valid alternative. When selecting health status instruments one should carefully explore and pretest possible health status measures for specific clinical or study settings. 相似文献
86.
87.
Alexander H. Enk Jürgen C. Becker Gerold Schuler 《Journal der Deutschen Dermatologischen Gesellschaft》2006,4(8):635-644
Immunotherapy has assumed increasing importance in the therapy of malignant melanoma. The main reason is the high immunogenicity of the tumor itself, so that an immune response against the tumor often exists even without immune stimulation. The goal of modern immunotherapeutic approaches is to augment these anti‐tumoral immune reactions to fight the tumor. Despite multiple successes, the ultimate breakthrough in the therapy of malignant melanoma has not yet been achieved. This overview summarizes the reasons for this lack of success and highlights future strategies for more successful therapy of malignant melanoma. 相似文献
88.
Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain 总被引:1,自引:0,他引:1
Hofmann S Thoma-Uszynski S Hunziker T Bernard P Koebnick C Stauber A Schuler G Borradori L Hertl M 《The Journal of investigative dermatology》2002,119(5):1065-1073
Bullous pemphigoid, the most common autoimmune subepidermal bullous disorder, is associated with autoantibodies targeting antigenic sites clustered within the extracellular domain of BP180. To investigate epitope and subclass specificity of autoantibodies in bullous pemphigoid, we developed an enzyme-linked immunosorbent assay utilizing baculovirus-expressed recombinant forms of the NH2- and COOH-terminal regions of the extracellular domain of BP180 and examined sera obtained from patients with active bullous pemphigoid (n=116) and controls (n=100). Ninety-three (80%) and 54 (47%) of the 116 bullous pemphigoid sera recognized the NH2- and COOH-terminal regions, respectively, of the extracellular domain of BP180. Detailed analysis demonstrates that (i) this novel enzyme-linked immunosorbent assay is highly specific (98%) and sensitive (93%) as 108 of 116 bullous pemphigoid sera reacted with at least one of the baculovirus-derived recombinants, (ii) in active bullous pemphigoid, autoantibodies against the NH2-terminus of the extracellular domain of BP180 were predominantly of the IgG1 class, whereas a dual IgG1 and IgG4 response to this region was related to a more severe skin involvement, (iii) autoreactivity against both the NH2- and COOH-terminal regions was more frequently detected in patients with mucosal lesions, and (iv) levels of IgG (and IgG1) against the NH2-terminal, but not against the COOH-terminal portion of the extracellular domain of BP180, reflected disease severity indicating that autoantibodies against the NH2-terminus are critical in the pathogenesis of bullous pemphigoid. In conclusion, this novel enzyme-linked immunosorbent assay represents a highly sensitive and specific assay for rapid diagnosis of bullous pemphigoid and related disorders and may provide predictive parameters for the management of bullous pemphigoid patients. 相似文献
89.
Lisa Holper Michaela Coenen Andrea Weise Gerold Stucki Alarcos Cieza Jürg Kesselring 《Journal of neurology》2010,257(1):103-113
The objective of this study was to explore whether it is possible to describe based on the International Classification of
Functioning, Disability and Health (ICF) relevant aspects of functioning and disability affected in multiple sclerosis (MS)
as well as environmental factors relevant to persons with MS. The specific aim was to identify most relevant ‘Body functions’,
‘Body structures’, ‘Activities and participation’, as well as ‘Environmental factors’ in patients with MS using the ICF. Additionally,
different MS forms were compared with respect to the identified problems. A multi-centre study was conducted in an empirical
cross-sectional design. Data from 205 individuals with MS were collected in rehabilitation centres: disease related data,
socio-demographic data, single interviews based on the Extended ICF Checklist and a patient questionnaire including ratings
on general health and functioning status, Beck Depression Inventory II (BDI-II) and Comorbidity Questionnaire (SCQ). The 129
ICF categories identified represent a comprehensive classification of functioning in MS from the clinical perspective. Differences
between MS forms were observed for several ICF categories, EDSS, general health and functioning status, but not for BDI and
SCQ. The study showed that it is possible to describe based on the ICF the spectrum in functioning and disability affected
in MS as well as environmental factors relevant to persons with MS. 相似文献
90.
Kudo M Imanaka K Chida N Nakachi K Tak WY Takayama T Yoon JH Hori T Kumada H Hayashi N Kaneko S Tsubouchi H Suh DJ Furuse J Okusaka T Tanaka K Matsui O Wada M Yamaguchi I Ohya T Meinhardt G Okita K 《European journal of cancer (Oxford, England : 1990)》2011,47(14):2117-2127
BackgroundIn Japan and South Korea, transarterial chemoembolisation (TACE) is an important locoregional treatment for patients with unresectable hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, has been shown effective and safe in patients with advanced HCC. This phase III trial assessed the efficacy and safety of sorafenib in Japanese and Korean patients with unresectable HCC who responded to TACE.MethodsPatients (n = 458) with unresectable HCC, Child-Pugh class A cirrhosis and ?25% tumour necrosis/shrinkage 1–3 months after 1 or 2 TACE sessions were randomised 1:1 to sorafenib 400 mg bid or placebo and treated until progression/recurrence or unacceptable toxicity. Primary end-point was time to progression/recurrence (TTP). Secondary end-point was overall survival (OS).FindingsBaseline characteristics in the two groups were similar; >50% of patients started sorafenib >9 weeks after TACE. Median TTP in the sorafenib and placebo groups was 5.4 and 3.7 months, respectively (hazard ratio (HR), 0.87; 95% confidence interval (CI), 0.70–1.09; P = 0.252). HR (sorafenib/placebo) for OS was 1.06 (95% CI, 0.69–1.64; P = 0.790). Median daily dose of sorafenib was 386 mg, with 73% of patients having dose reductions and 91% having dose interruptions. Median administration of sorafenib and placebo was 17.1 and 20.1 weeks, respectively. No unexpected adverse events were observed.InterpretationThis trial, conducted prior to the reporting of registrational phase III trials, found that sorafenib did not significantly prolong TTP in patients who responded to TACE. This may have been due to delays in starting sorafenib after TACE and/or low daily sorafenib doses. 相似文献